Folate-FITC

DRACPC ID  DRACPC0036

Active Ingredients   Folate-FITC

Description  A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity.

Synonyms  EC-17; Folate Fluorescein Isothiocyanate Conjugate; L-Glutamine, N2-(4-(((2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-N-(2-((((3',6'-dihydroxy-3-oxospiro(isobenzofuran-1(3H),9'-(9H)xanthen)-5-yl)amino)thioxomethyl)amino)ethyl)-; Folate-FITC

Type  Small Molecule

Disease  Ovarian Cancer, Renal Cell Carcinoma

Classification

  

Amino acid and derivative Cancer targeted Conjugates

Structure Information


Molecular Formula  C42H36N10O10S

Molecular Weight  872.9

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-2-[1-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}phenyl)-N-{2-[({3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-1,9'-xanthene]-5-yl}carbamothioyl)amino]ethyl}formamido]-4-carbamoylbutanoic acid

InChI  InChI=1S/C42H36N10O10S/c43-33(55)12-11-30(38(58)59)52(37(57)20-1-3-21(4-2-20)46-18-23-19-47-35-34(48-23)36(56)51-40(44)50-35)14-13-45-41(63)49-22-5-8-27-26(15-22)39(60)62-42(27)28-9-6-24(53)16-31(28)61-32-17-25(54)7-10-29(32)42/h1-10,15-17,19,30,46,53-54H,11-14,18H2,(H2,43,55)(H,58,59)(H2,45,49,63)(H3,44,47,50,51,56)/t30-/m0/s1

InChI_Key ZMTAPBHUSYTHBY-PMERELPUSA-N

SMILES  S=C(NC1=CC2=C(C=C1)C3(C4=C(OC5=C3C=CC(O)=C5)C=C(O)C=C4)OC2=O)NCCN(C(C6=CC=C(NCC(N=C78)=CN=C8N=C(N)NC7=O)C=C6)=O)[C@@H](CCC(N)=O)C(O)=O

External Codes


PubChem CID  135564966

DrugBank Accession Number  DB12559

NCI Thesaurus Code  C62479  

UNII  V7YQ6134AE   GSRS

CAS  583037-91-6



Drug approval


Drug indication
    Folate Fitc has been used in trials studying the diagnostic or treatment of Ovarian Cancer, Renal Cell Carcinoma and other cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01994369 A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Surgery Presenting Breast Cancer Resectable Breast Cancer Phase 1 Diagnostic
NCT02000778 A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Intraoperative Detection of Occult Ovarian Carcinoma Ovarian Cancer Phase 1 Diagnostic
NCT01778933 A Pilot and Feasibility Study Of The Imaging Potential Of EC17 In Subjects Undergoing Surgery Presenting With Renal Nodules Renal Cell Carcinoma Phase 1 Diagnostic
NCT01778920 Intraoperative Imaging of Pulmonary Adenocarcinoma Lung and Pleural Malignancies; Neoplasms; Nodules; Adenocarcinoma Phase 1 Diagnostic
NCT00485563 A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma Renal Cell Carcinoma Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.